CytomX Therapeutics, Inc.
Customers
0
None disclosed
Suppliers
1
0 disclosed
Latest period
Dec 31, 2019
10-K filed 2022-02-28
Suppliers 1
Companies that disclose CTMX as a major customer, as a share of their own revenue. 0 active, 1 lapsed.
| Company | % of their revenue | Est. $ from CTMX | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| ImmunoGen, Inc. ImmunoGen, Inc. |
13% | $10.7M | FY 2019-12-31 | Lapsed Last seen 2019-12-31 |
10-K 2022-02-28 | |
Comprehensive loss is comprised of the Company’s net loss for all periods presented.Segment InformationDuring all periods presented, the Company continued to operate in one reportable business segment under the management approach of ASC 280, Segment Reporting, which is the business of the discovery and development of ADCs for the treatment of cancer.The percentages of revenues recognized from significant customers of the Company in the years ended December 31, 2021, 2020, and 2019 are included in the following table: Year Ended December 31, Collaborative Partner: 2021 2020 2019Roche 67% 53% 64%Huadong 24% -% -%Jazz -% 46% 18%CytomX -% -% 13% There were no other customers of the Company with significant revenues in the periods presented.Recently Adopted Accounting PronouncementsIn December 2019, the FASB issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify the accounting for income taxes. | ||||||
Named as competitors
Companies this filer names as competitors.
Alerts are coming
Get an email when CTMX's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.